The NIH has launched a new collaboration with 11 biopharmaceutical companies and four academic cancer centers to identify the most effective biomarkers for immunotherapy. The public–private partnership will analyze patient samples from clinical trials and aims to develop a standard panel of biomarkers to determine which patients are likely to benefit from immunotherapy and to track their responses.

中文翻译：

---

美国国立卫生研究院计划旨在改善免疫疗法

美国国立卫生研究院（NIH）与11家生物制药公司和4个学术癌症中心展开了新的合作，以鉴定最有效的免疫疗法生物标志物。公私合作伙伴关系将分析来自临床试验的患者样本，旨在建立标准的生物标志物检测小组，以确定哪些患者可能会受益于免疫疗法并追踪其反应。